All In Biotech

Drug Trial Radar · NCT05624450

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,527 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,527

Planned (sponsor's estimate)

Start

Dec 13, 2022

Primary completion

Nov 4, 2027

Study completion Nov 4, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

Conditions

  • Viral Lung Infection and Acute Respiratory Failure

Interventions

  • TozorakimabDrug

    Single IV dose of tozorakimab on Day 1.

  • PlaceboDrug

    Single IV dose of matching placebo on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO)Time frame: by Day 28

Locations

473 sites in 39 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Not yet recruiting

  • Research Site

    Mobile, Alabama · Recruiting

  • Research Site

    Phoenix, Arizona · Completed

  • Research Site

    Phoenix, Arizona · Withdrawn

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Chula Vista, California · Withdrawn

  • Research Site

    Fresno, California · Recruiting

  • Research Site

    La Mesa, California · Withdrawn

  • Research Site

    Los Angeles, California · Withdrawn

  • Research Site

    Newport Beach, California · Recruiting

  • Research Site

    Torrance, California · Recruiting

  • Research Site

    Colorado Springs, Colorado · Recruiting

  • Research Site

    Denver, Colorado · Withdrawn

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Bradenton, Florida · Completed

  • Research Site

    Bradenton, Florida · Withdrawn

  • Research Site

    Gainesville, Florida · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Lakeland, Florida · Recruiting

  • Research Site

    Miami, Florida · Withdrawn

  • Research Site

    South Pasadena, Florida · Completed

  • Research Site

    St. Petersburg, Florida · Withdrawn

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Withdrawn

  • Research Site

    Boise, Idaho · Recruiting

  • Research Site

    Chicago, Illinois · Completed

  • Research Site

    Elmhurst, Illinois · Withdrawn

  • Research Site

    Evanston, Illinois · Recruiting

  • Research Site

    Fort Wayne, Indiana · Withdrawn

  • Research Site

    Iowa City, Iowa · Withdrawn

  • Research Site

    Kansas City, Kansas · Withdrawn

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Baton Rouge, Louisiana · Recruiting

  • Research Site

    New Orleans, Louisiana · Withdrawn

  • Research Site

    Shreveport, Louisiana · Completed

  • Research Site

    Annapolis, Maryland · Recruiting

  • Research Site

    Silver Spring, Maryland · Completed

  • Research Site

    Springfield, Massachusetts · Completed

  • Research Site

    Worcester, Massachusetts · Completed

  • Research Site

    Detroit, Michigan · Recruiting

Showing 40 of 473 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.